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ABSTRACT 
Objective: Earlier works have reported on the effectiveness of the compounds of the group of substituted 5R1, 6R2, 3,4-thiadiasine-2-amines for 
treating experimental myocardial infarction, conditioned by the immune-modifying action of the compound. The purpose of this study was to 
evaluate the action of the L17 compound of the group of substituted 5R1, 6R2, 3,4-thiadiasine-2-amines on the extent of injury and the possible 
recurrence of experimental myocardial infarction by the dynamic assessment of transaminase activity in blood and myocardial homogenate 
(tissue). 
Methods: Modelling of myocardial infarction in rats was performed in accordance with the author’s modification of the standard ligation model. 
Tissue enzyme activity of LDH and CK-MB was evaluated at days 1, 7, and 14. 
Results: According to the results, the decrease in LDH 1-2 activity in tissue (after experimental myocardial infarction) corresponded to the increase 
in enzyme activity in blood on the first day of the experiment. However, on the seventh day of the experiment, the decrease of LDH 1-2 activities in 
the tissue of animals treated with L17 compound corresponded with the decrease of LDH activity in blood, while in non-treated animals the relation 
between the enzyme levels in blood and tissue was typical for the onset of MI. 
Conclusions: The evaluation of enzyme levels in myocardial tissue confirms previouslyreported data that the administration of a thiadiazine 
compounds prevents the recurrence and decreases the size of experimental myocardial infarction. 
Keywords: Enzymes, L-17 compound, Myocardial infarction, Thiadiazines, Tissue enzymes. 
 
INTRODUCTION 
Despite the discovery of new methods for diagnosing myocardial 
infarction (MI), the assessment of the level of a biomarker remains 
advantageous compared with other diagnostic techniques. First, 
biomarkers can help clinicians efficiently formulate a differential 
diagnosis. Second, because biomarker levels often correlate with the 
severity of a disease, they can be used to guide therapy. Third, some 
biomarkers provide prognostic value [1]. And last but not least, the 
cost of assessment (via biochemical analyses) of biomarkers is much 
lower than the cost of procedures with similar predictive capabilities.  
Irreversible myocardial necrosis is the hallmark of acute myocardial 
infarction. Myocardial injury leads to the release of specific cytosolic 
substances that can be used as markers of injury [1]. These markers 
includecreatine phosphokinase (CK-MB), aspartate amino 
transferase (AST), alanine aminotransferase (ALT), lactate 
dehydrogenase (LDH), creatine phosphokinase (CPK), and others 
[2]. The activity of these enzymes increases dramatically in blood 
serum after the onset of ischemia, which is the indicator of the 
extent and depth of tissue damage [3]. 
Earlier works have reported on the effectiveness of the L17 compound of 
the group of substituted 5R1,6R,2,3,4-thiadiasine-2-amines for treating 
experimental myocardial infarction, conditioned by the immune-
modifying action of the compound. These studies assert that a reduction 
in neutrophilous infiltration and activation of lympho/monocytic 
infiltration occurs in the nidus of inflammation [4, 5]. 
The purpose of this study was to evaluate the action of the L17 
compound on the extent of injury and the possible recurrence of 
experimental MI by the dynamic assessment of transaminase 
activity in blood and myocardial homogenate (tissue). 
LDH, AST, and CPK activity was measured, because the basal levels 
of these enzymes in the myocardium are higher than that in other 
tissues and that is why an increase in activity of these enzymes is a 
very sensitive and specific marker of acute heart damage, especially 
MI [6]. 
MATERIALS AND METHODS 
Test compound 
The test compound L-17 from the group of 5-phenyl substituted-6H-
1,3,4-thiadiazine-2-amines studied in these experiments has been 
proven to have a biological effect [4, 5, 7-9]. 
Animal preparation 
The experiment was carried out on healthy, sexually mature, 
nonlinear albino male rats. The animals used in the tests were 
quarantined in the vivarium of the Institute of Immunology and 
Physiology of the Ural Division of Russian Academy of Science 
(Yekaterinburg, Russia). The animals had no symptoms of any 
disease. All animals were housed under equivalent conditions and 
were fed according to the customary schedule. All experimental 
procedures performed on the animals were approved by the 
Institute of Animal Care and Use Committee at the Institute of 
Immunology and Physiology of the Ural Division of RAS (# S-FL17-
2014-25) and were performed in accordance with the principles 
formulated by the European Convention for the Protection of 
Vertebrate Animals used for Experimental and Other Scientific 
Purposes (Strasbourg, France, 18.03.1986), APS's Guiding Principles 
in the Care and Use of Vertebrate Animals in Research and Training, 
and in accordance with the Laboratory Practice Regulations of RF 
(Ministry of Public Health Order no. 267 from 19.06.2003) [10]. 
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All animals undergoing surgery received a similar level of care and 
attention. Surgery was performed with the use of aseptic techniques. 
Instruments were sterile. For separate experiments, the procedure 
was as follows. After an overnight fast, the rats were anesthetized 
with ether and the experimental MI was performed. At the end, all 
rats were anesthetized with ether and decapitated. Diazepam (2.5 
mg/kg) was used to lessen the dosage of general anesthetic and to 
produce a smoother induction and recovery [11, 12].  
Modelling of MI in rats was performed in accordance with the 
author’s modification of the standard ligation model (RF Patent No 
2407062 of 20/12/2010) [4]. After surgery, every rat was 
maintained in a separate, labelled cage. The methods have been 
previously reported [4, 5]. 
Experimental protocol 
The animals were divided into four groups: Group A included 5 
intact animals with an average body weight of 220 g each; Group B 
(sham-operated) included 10 animals (average body weight 216 g 
each) that underwent a thoracotomy (only plasma enzyme levels 
were detected [4, 5]); Group C (MI-group) included 10 animals 
(average body weight 232 g each) that underwent experimental MI, 
but no preparation was administered; and Group D included 15 
animals (average body weight 210 g each) that had undergone the 
experimental MI and received intraperitoneal injection of the L-17 
compound, dosed at 40 mg/kg an hour after surgery. Later, a 40-
mg/kg dose of L-17 was repeatedly injected as often as once every 
24 hours.  
Laboratory testing 
For biochemical analysis, 3 ml of blood was obtained via a heart 
puncture for subsequent centrifugation and serum separation. 
Serum activity of CK-MB, ALT, AST, LDH (isoenzymes 1 and 2) before 
and during the process of MI development was investigated on days 
1, 5, and 7 of the experiment. 
Tissue enzyme activity of LDH and CK-MB was evaluated at days 1, 7, 
and 14. For this evaluation, a 10% myocardial homogenate was 
prepared. The weighed portion of myocardial tissue with 
physiological saline (1.0 ml of physiological saline per 100 mg of 
tissue) was homogenized for 1 minute by placing a glass containing 
tissue samples into a cup containing ice. Then, the homogenate was 
centrifuged for 5 minutes at 3000 rpm. Subsequently, the 10% 
homogenate was diluted 20 times.  
The activity of the enzymes was investigated in the resulting 
solution (reagent kits LDH B 23.01. and CK-NAC-03/13 "Vital 
Development Corporation", Saint-Petersburg, Russia). 
Statistical analysis 
The Student t test and a nonparametric Mann-Whitney test were 
applied to compare the groups. The Statistica Six Sigma Release 7 
computer program was used for mathematical data processing. All 
the data are expressed as mean±SD. P<0.05 was considered 
statistically significant. 
RESULTS 
The results of routine biochemical studies of enzyme activity 
(markers of myocardial infarction) in the serum have been 
previously reported [4]. 
According to the results of biochemical analyses, the amino 
transferring enzyme levels in the serum of sham-operated rats 
(Group B) reliably exceeded the corresponding indicators of healthy 
rats in Group A. Enzyme activity returned to basal levels (close to the 
values of intact animals) on day 7 of the experiment. 
Throughout the study, in animals with experimental infarction 
without treatment (Group C), determined levels of almost all 
enzymes exceeded that of intact animals as well as the enzyme 
indicators in sham-operated animals. Only on the fifth day of 
experimental infarction were the activity indicators AST (17.4±3.0 
U/l), ALT (18.7±3.31 U/l), and LDG 1-2 (262.3±22.1 U/l) 
significantly decreased compared with those on the first day, 
although these rates remained higher than in Groups A and B [4]. 
Of interest is the comparison of serum enzymes between Groups C 
and D. According to the data obtained, throughout the entire 
experiment, the levels of AST, ALT, and CK-MB in Group D animals 
were significantly lower than that in the blood of Group C animals.  
In addition to the biochemical analyses, the evaluation of enzyme 
activity in myocardial tissue was performed (tables 1-4). 
Results of the biochemical investigation of LDH activity are 
presented in tables 1-2. 
  
Table 1: LDH activity in rats with myocardial infarction in the myocardial tissue homogenate (based on milligrams of protein tissue 
homogenate) 
Time Intact animals, (Group A), 
n=5 М±m 
Experimental infarction without 
treatment (Group C), n=10 М±m 
Experimental infarction with L17 compound 
administration (Group D), n=15 М±m 
total LDH activity,U/g (units per grams) 
1st day 5,10±0,31 3,86±0,45* 3,83±0,10* 
7th day  4,37±0,29 3,73±0,37*# 
14th 
day 
 4,08±0,54 4,22±0,24 
LDH 1-2 isoenzyme activity  
1st day 5,06±0,31 (99,4 %) 3,45±0,11* (89,4 %) 3,81±0,36* (99,5 %) 
7th day  3,76±0,11* (86,0 %) 3,31±0,28* (88,7 %) 
14th 
day 
 3,92±0,17* (96,1 %) 3,46±0,26* (82,0 %) 
Note: * statistical reliability with group A was significant (р<0.05); # statistical reliability between Groups C and D was significant (р<0.05). 
 
Analysis of total LDH activity in rats with experimental MI (Groups C 
and D) in the myocardial tissue homogenate (in terms of milligrams 
of tissue homogenate protein) revealed significantly lower levels of 
activity compared with that in Group A animals on day 1 of the 
experiment (3.86±0.45 U/g protein in group C and 3.83±0.10 U/g 
protein in group D vs. 5.10±0.31 U/g protein group A).  
Analyses of LDH 1-2 iso enzyme activities showed that the values of 
LDH1-2 did not differ significantly between Groups C and D but were 
significantly lower than the values for Group A animals (table 1). 
Moreover on the seventh day of the experiment, LDH 1-2 activity in 
the myocardial tissue of Group D animals was significantly lower 
than not only the values for Group A animals (3.31±0.28 U/g protein 
in Group D versus 3.73±0.375, 10±0.31 U/g protein in group A), but 
also the values for Group C animals (3.31±0.28 U/g protein in group 
D vs. 4.37±0.29 U/g of protein in B). 
Analysis of total LDH activity in rats with experimental MI (Groups C 
and D) in the myocardial tissue homogenate (in terms of gram wet 
weight tissue) revealed the absence of any significant differences 
between the experimental groups. However, analyses of LDH 1-2 iso 
enzyme activities showed that the values of activity in Group C 
animals were significantly lower than the values of Group A animals 
on days 1 and 7. 
Alexey et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 6, 147-151 
149 
Table 2: LDH activity in rats with myocardial infarction in the myocardial tissue homogenate (in terms of gram wet weight tissue) 
Time Intact animals, (Group 
A), n=5 М±m 
Experimental infarction without 
treatment (Group C), n=10 М±m 
Experimental infarction with L17 compound 
administration (Group D), n=15 М±m 
total LDH activity,U/g (units per grams) 
1st day 331,5±7,8 332,4±39,9 309,2±8,1 
7th day  326,0±24,3 348,6±35,6 
14th 
day 
 335,7±43,9 381,0±20,7 
LDH 1-2 isoenzyme activity (% activity) 
1st day 329,5±7,9 (99,4%) 297,4±8,7* (89,5%) 308,1±29,3 (99,6%) 
7th day  280,6±8,5* (86,1%) 309,8±26,2 (88,9%) 
14th 
day 
 322,2±13,2 (96,0%) 312,5±22,0 (82,0%) 
Note: * statistical reliability with group A was significant (р<0.05). 
 
Table 3: CPK activity in rats with myocardial infarction in the myocardial tissue homogenate (in terms of gram wet weight tissue) 
Time Intact animals,  
(Group A), n=5 М±m 
Experimental infarction without treatment 
(Group C), n=10 М±m 
Experimental infarction with L17 compound 
administration (Group D), n=15 М±m 
total CPK activity, U/g(units per grams) 
1st day 3,34±0,23 5,33±0,39* 5,10±0,38* 
7th day  5,66±0,44* 3,46±0,30# 
14th 
day 
 5,18±0,33* 5,18±0,28* 
Note: * statistical reliability with group A was significant (р<0.05); # statistical reliability between Groups C and D was significant (р<0.05). 
 
According to the study data, total CPK activity (in terms of 
milligrams of tissue homogenate protein) in Group C animals was 
significantly higher than the activity of this enzyme in Group A 
animals. However, because of L17 compound administration (Group 
D) on day 7 of the experiment, total CPK activity was significantly 
lower (3.46±0.30 U/g protein) than that in Group C (5.66±0.44 U/g 
protein) animals and did not differ from the values for intact animals 
(Group A). 
 
Table 4: CPK activity in rats with myocardial infarction in the myocardial tissue homogenate (based on milligrams of protein tissue 
homogenate) 
Time Intact animals,  
(Group A), n=5 М±m 
Experimental infarction without treatment 
(Group C), n=10 М±m 
Experimental infarction with L17 compound 
administration (Group D), n=15 М±m 
LDH activity, U/g (units per grams) 
1st day 215,5±15,7 458,9±31,2* 411,6±28,6* 
7th day  421,5±29,1* 323,6±26,9* # 
14th 
day 
 425,9±26,2* 467,7±26,8* 
Note: * statistical reliability with group A was significant (р<0.05); # statistical reliability between Groups C and D was significant (р<0.05). 
 
A similar pattern in the values of CPK activity was recorded during 
the study analysis in terms of gram wet weight tissue. According to 
the results, total CPK activity in Group D animals was significantly 
lower (323.6±26.9 U/g protein) than that in Group C (421.5±29.1 
U/g protein) animals. 
DISCUSSION 
All transaminases, including the CPK-MB, are present in skeletal 
muscles, and even average damage to muscles can increase their 
levels in the blood to abnormal values [12]. Therefore, of special 
significance was the comparison of enzyme levels in animals with 
(Groups C and D) and without myocardial tissue damage. 
The most sensitive tests in MI diagnostics are the evaluation of the CPK, 
AST, and LDH activity in blood serum [3, 6]. For example, AST activity 
after MI can increase 2 to 20 times, but during angina it usually remains 
within normal values [13, 14]; the gradual decrease in AST and ALT 
levels is of special importance for the diagnosis of MI [6, 13-16].  
Total LDH (there are 5 LDH isoenzymes) is known to be the late 
biomarker of MI and reacts later to injury than other enzymes do. 
However, LDH1 isoenzyme present mostly in the heart is considered 
more informative than other enzymes, because it increases after MI 
before other isoenzymes and can increase against the normal values 
of total LDH [15].  
As for the CPK-MB, it is located almost in the myocardium, and for 
that reason, its increase is a highly specific and sensitive indicator of 
cardiomyocyte damage [17].  
In contrast to the abovementioned enzymes, the increase of ALT 
levels after MI is not so significant and sharp, but its lower levels in 
comparison with levels of AST (ALT/AST ratio) are of great 
diagnostic value, because it excludes liver pathology [18, 19]. 
According to previous data [4, 5], the significant increase in 
transaminase activity on the first day of the experiment indicated 
the effectiveness of the experimental MI model used in the study. 
The increase in enzyme activity on the fifth day of the experiment is 
also common in acute MI development [6]. 
The influence of L17 compound administration on tissue 
enzyme levels 
Significant lower CPK activity in Group D animals (on the 
background of L17 compound administration) was the indirect 
confirmation of the compound’s action in reducing the size of 
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experimental MI, because, according to MRI studies, CPK activity 
strongly correlates with the area of MI [20]. 
Total LDH activity (based on milligrams of protein tissue 
homogenate) in experimental groups (Group C and D) did not differ 
significantly from the values of intact animals. However, the levels of 
cardio-specific LDH 1-2 significantly declined throughout the study, 
both in Groups C and D, compared with that in control group (Group 
A) values.  
The principal differences between the experimental groups and thus 
the action of the L17 compound can be revealed only after the 
comparison of enzyme activity in blood [4, 5] and tissue. According 
to the results, the decrease in LDH 1-2 activity in tissue (both in 
Group C and D) corresponded to the increase in enzyme activity in 
blood on the first day of the experiment, and was in accordance with 
data in the literature [3, 21-23].  
However, on the seventh day of the experiment, the decrease of 
LDH 1-2 activity in the tissue of Group D animals corresponded 
with the decrease of LDH activity in blood (229.7±60.6 U/l), while 
in group C animals the relation between the enzyme levels in 
blood (345.5±52.9 U/l) and tissue was typical for the onset of MI 
[21, 24]. 
The changes in CPK activity revealed a similar pattern. On the 
seventh day of the experiment, the decrease in CPK activity almost to 
the values of intact animals was observed both in the blood 
(108±16.8 U/l vs 248.1±41.5 in Group C) and the tissue of Group D 
animals (on the background of L17 compound administration).  
The described changes in the dynamics and relationships between 
LDH and CPK levels in blood and tissue confirmed the occurrence of 
recurrent MI (as a consequence, the increase in tissue damage 
volume) in animals in Group C and prevention of its development in 
animals in Group D.  
Thus, the evaluation of enzyme levels in myocardial tissue confirms 
previously reported data that the administration of a thiadiazine 
compound prevents the recurrence and decreases the size of 
experimental MI. 
CONCLUSION 
According to the previous data, administration of L17 compound 
strongly induced the activation of the apoptosis process after 
experimental MI. The activation of the intrinsic apoptosis pathway 
(CD 95 marker) was observed from the first day of the experiment, 
and activation of the extrinsic pathway (P53 marker) was found on 
the seventh day of the experiment [9]. 
These findings, coupled with data that transaminase (AST) activity 
strongly correlates with the size of the necrotic area after MI [25-
27], allow us to assume that apoptosis activation is one of the 
mechanisms of L17 action. According to this hypothesis, 
cardiomyocyte apoptosis activation reduces the number of cells that 
die by necrosis and as a result decreases enzyme levels. 
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